Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2004, for WellPoint, Inc. (formerly Anthem, Inc.). The reporting period is significantly impacted by the completion of the merger with WellPoint Health Networks Inc. (WHN) on November 30, 2004. Following the merger, WellPoint became the largest publicly traded commercial health benefits company in the U.S. by membership, serving approximately 27.7 million medical members. The company operates as an independent licensee of the Blue Cross Blue Shield Association (BCBSA) in 13 states and serves customers nationally under the HealthLink and UniCare brands. The company is organized into three reportable segments: Health Care, Specialty, and Other.
Key Financial Metrics
| Metric | 2004 | 2003 |
|---|---|---|
| Total Operating Revenue | $20,460.9 million | $16,487.1 million |
| Total Revenue (incl. investment income) | $20,815.1 million | $16,781.4 million |
| Net Income | $960.1 million | $774.3 million |
| Diluted EPS | $6.10 | $5.45 |
| Benefit Expense Ratio | 82.0% | 80.8% |
| Selling, General & Admin (SG&A) Ratio | 17.0% | 18.8% |
| Long-Term Debt | $4,276.7 million | $1,662.8 million |
| Debt-to-Total Capital Ratio | 18.5% | 21.7% |
| Cash and Investments | $15,792.2 million | $7,478.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Total operating revenue increased 24% to $20.46 billion, driven primarily by the inclusion of WHN operations (one month in 2004) and premium rate increases in Large Group and Individual/Small Group businesses.
- Profitability: Net income rose 24% to $960.1 million. Diluted earnings per share increased 12% to $6.10.
- Expense Trends: The benefit expense ratio increased 120 basis points to 82.0%, reflecting higher medical cost trends (outpatient and pharmacy) and the normalization of reserves after favorable development in 2003. Conversely, the SG&A ratio improved by 180 basis points to 17.0% due to operating leverage.
- Debt Structure: Long-term debt increased by approximately $2.6 billion to $4.3 billion, primarily to fund the WHN merger. The company incurred a $146.1 million loss on the repurchase of high-coupon surplus notes and recorded $61.5 million in merger-related undertakings.
- Membership: On a comparable basis (assuming the merger occurred in 2003), medical membership grew 6% to 27.7 million, with significant gains in National Accounts (20%) and BlueCard (18%) segments.
Guidance, Outlook, and Risks
Management Commentary: Management attributes growth to the successful integration of WHN, disciplined underwriting, and the value of the BCBS network. The company expects to maintain investment-grade debt ratings. Cost of care trends were just under 10% for 2004, driven by outpatient services and pharmacy costs. The company is actively pursuing performance-based contracts and disease management programs to mitigate future cost inflation.
Risks and Contingencies:
- Legal Proceedings: The company is a defendant in consolidated multidistrict litigation (MDL) alleging RICO violations by managed care companies. Trial is scheduled for September 2005. The company intends to vigorously defend these claims but notes outcomes are uncertain.
- Regulatory Environment: Operations are subject to extensive state and federal regulation, including small group reform laws, Medicare reimbursement changes, and potential legislative changes regarding ERISA pre-emption and provider access.
- Medical Claims Reserves: The liability for medical claims payable ($4.2 billion) is a critical estimate. A 1% variance in the estimated liability could impact net income by approximately $27.3 million.
- Investment Risk: The company holds $13.6 billion in investments. While the portfolio is high quality (average AA rating), it is exposed to interest rate and credit risks. A 100 basis point increase in interest rates would decrease the fair value of the fixed maturity portfolio by approximately $476.7 million.
Key Facts for Investor Verification
- Merger Integration: Verify the realization of anticipated synergies and operating efficiencies from the WHN merger, which was completed late in the fiscal year.
- Medical Cost Trends: Monitor the sustainability of the 82.0% benefit expense ratio and the company's ability to negotiate provider contracts to offset rising outpatient and pharmacy costs.
- Legal Exposure: Track the status of the MDL RICO litigation and the potential for significant punitive damages or settlements.
- Debt Servicing: Confirm the company's ability to service the increased debt load ($4.3 billion) and maintain its investment-grade credit ratings (BBB+/A-/Baa1).
- Reserve Adequacy: Review quarterly updates on medical claims payable development to ensure prior year reserve estimates remain accurate.